Literature DB >> 22367021

High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk.

Polat Dura1, Jody Salomon, Rene H M Te Morsche, Hennie M J Roelofs, Jon O Kristinsson, Theo Wobbes, Ben J M Witteman, Adriaan C I T L Tan, Joost P H Drenth, Wilbert H M Peters.   

Abstract

Esophageal cancer (EC) has a globally increasing incidence with poor curative treatment options and survival rates. Environmental and dietary factors have crucial roles in esophageal carcinogenesis. Polymorphisms in the UGT genes, a superfamily of enzymes essential for the detoxification of carcinogens, may alter enzyme activity and subsequently may play a role in EC etiology. Rather than solely establishing differences in genotype distribution, we investigated whether functional polymorphisms in UGT genes that can predict enzyme activity in vivo, may influence EC risk. A case-control study including 351 Caucasian EC patients and 592 Caucasian controls was conducted and polymorphisms in seven UGT genes were determined, using the polymerase chain reaction. On the basis of allelic in vitro enzyme activity measurements, genotypes were categorized according to their predicted in vivo enzyme activity into high, medium and low categories. Predicted enzyme activity groups were combined and compared between patients and controls. The UGT1A1 and UGT1A8 predicted high enzyme activity genotypes were significantly more (OR=1.62; 95% CI, 1.02-2.56) and less frequent (OR=0.36; 95% CI, 0.15-0.84) among patients with esophageal squamous cell carcinoma (ESCC), respectively. High (OR=0.42; 95% CI, 0.22-0.84) and medium (OR=0.25; 95% CI, 0.12-0.52) activity UGT2B4 genotypes were significantly less often present in ESCC patients. No association was detected between UGT genotypes and esophageal adenocarcinoma (EAC) risk. Polymorphisms in UGT genes, resulting in altered enzyme activity genotypes, do not seem modifiers of EAC risk. However, the predicted high activity UGT1A1 genotype, associated with low serum levels of the antioxidant bilirubin, was associated with an increased ESCC risk. The UGT1A8 and UGT2B4 genotypes associated with decreased predicted enzyme activities, were significantly associated with an increased risk of ESCC, probably by a decreased detoxification of carcinogens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367021     DOI: 10.3892/ijo.2012.1385

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

1.  Polymorphisms in UGT2B4 and susceptibility to pancreatic cancer.

Authors:  Xu Che; Dianke Yu; Zongyong Wu; Jianwei Zhang; Yintai Chen; Yaling Han; Chenfeng Wang; Jun Qi
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Regulation profile of phosphatidylcholines (PCs) and lysophosphatidylcholines (LPCs) components towards UDP-glucuronosyltransferases (UGTs) isoforms.

Authors:  Xin Gao; Hengyan Qu; Chun-Zhi Ai; Yun-Feng Cao; Ting Huang; Jian-Xing Chen; Jia Zeng; Xiao-Yu Sun; Mo Hong; Frank J Gonzalez; Zeyuan Liu; Zhong-Ze Fang
Journal:  Xenobiotica       Date:  2014-09-26       Impact factor: 1.908

3.  Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.

Authors:  Dominique Scherer; Lisel M Koepl; Elizabeth M Poole; Yesilda Balavarca; Liren Xiao; John A Baron; Li Hsu; Anna E Coghill; Peter T Campbell; Sarah E Kleinstein; Jane C Figueiredo; Johanna W Lampe; Katharina Buck; John D Potter; Richard J Kulmacz; Mark A Jenkins; John L Hopper; Aung K Win; Polly A Newcomb; Cornelia M Ulrich; Karen W Makar
Journal:  Genes Chromosomes Cancer       Date:  2014-03-28       Impact factor: 5.006

4.  Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.

Authors:  Dongxiao Sun; Nathan R Jones; Andrea Manni; Philip Lazarus
Journal:  Cancer Prev Res (Phila)       Date:  2013-05-16

5.  Evaluating the beneficial and detrimental effects of bile pigments in early and later life.

Authors:  Phyllis A Dennery
Journal:  Front Pharmacol       Date:  2012-06-22       Impact factor: 5.810

6.  Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer.

Authors:  Yongkuan Cao; Guohu Zhang; Peihong Wang; Jun Zhou; Wei Gan; Yaning Song; Ling Huang; Ya Zhang; Guode Luo; Jiaqing Gong; Lin Zhang
Journal:  BMC Gastroenterol       Date:  2017-01-05       Impact factor: 3.067

7.  Comparison of the inhibition capability of oleanolic acid and betulinic acid towards drug-metabolizing enzymes.

Authors:  Wei Xiao; Meng-Hou Lu
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

8.  Associations between Prediagnostic Circulating Bilirubin Levels and Risk of Gastrointestinal Cancers in the UK Biobank.

Authors:  Nazlisadat Seyed Khoei; Karl-Heinz Wagner; Robert Carreras-Torres; Marc J Gunter; Neil Murphy; Heinz Freisling
Journal:  Cancers (Basel)       Date:  2021-06-01       Impact factor: 6.575

9.  Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancer.

Authors:  Min Wang; De-Feng Sun; Shuai Wang; Ying Qing; Shuo Chen; Dong Wu; Ying-Min Lin; Ji-Zhuang Luo; Yan-Qing Li
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

10.  No role for glutathione S-transferase genotypes in Caucasian esophageal squamous cell or adenocarcinoma etiology: an European case-control study.

Authors:  Polat Dura; Jody Salomon; Rene H M Te Morsche; Hennie M J Roelofs; Jon O Kristinsson; Theo Wobbes; Ben J M Witteman; Adriaan C I T L Tan; Joost P H Drenth; Wilbert H M Peters
Journal:  BMC Gastroenterol       Date:  2013-06-03       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.